Counterfeit Ozempic on the Market!

The US Food and Drug Administration (FDA) has issued a warning regarding counterfeit semaglutide (Ozempic) products infiltrating the US drug supply.

Clinicians and patients should carefully inspect received product packages, particularly those labeled with lot number NAR0074 and serial number 430834149057, as these may be counterfeit.

The FDA, in collaboration with Ozempic manufacturer Novo Nordisk, is actively investigating the presence of counterfeit 1-mg injection units, with specific focus on pen needles. While details about the identity, quality, and safety of these drugs are not yet available, confirmed fake elements include pen needles, pen labels, healthcare professional and patient label information, and carton, raising concerns about potential infection risks.

The FDA emphasizes its commitment to investigating and addressing possible counterfeit products, collaborating with federal agencies and the private sector to safeguard the nation’s drug supply. Patients are strongly advised to obtain Ozempic only with a valid prescription from state-licensed pharmacies and to scrutinize the product for signs of counterfeiting. Notable distinctions between genuine and counterfeit products include packaging differences in the pen needle, where the counterfeit version’s paper tab reads “Novofine®” as opposed to the genuine one’s “Novofine® Plus.”

At least five adverse events associated with this specific lot have been reported, all non-serious and consistent with known gastrointestinal issues linked to the authentic product. Individuals encountering counterfeit products are urged to report them to the FDA’s consumer complaint coordinator or the criminal activity division. Stay informed and ensure the authenticity of your medications for your safety.

Source: FDA Warning